CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 11, 2009--
POZEN Inc. (NASDAQ:POZN), announced today that it will
release fourth quarter and year end 2008 results on February 25, 2009,
before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m.
Eastern Time with a discussion by POZEN management of the earnings and
business results. The webcast can be accessed on POZEN’s website at www.pozen.com
and will be archived and available for replay. The fourth quarter 2008
earnings release will be accessible in the News section of POZEN’s
POZEN is a pharmaceutical company committed to developing therapeutic
advancements for diseases with unmet medical needs where it can improve
efficacy, safety, and/or patient convenience. POZEN’s efforts are
focused primarily on the development of pharmaceutical products for the
treatment of acute and chronic pain and other pain-related conditions.
POZEN has development and commercialization alliances with
GlaxoSmithKline for Treximet®, which was recently approved by the
United States Food and Drug Administration for the acute treatment of
migraine attacks, with or without aura, in adults, and with AstraZeneca
for proprietary fixed dose combinations of naproxen with the proton pump
inhibitor esomeprazole magnesium in a single tablet for conditions such
as osteoarthritis and rheumatoid arthritis in patients who are at risk
for developing NSAID-associated gastric ulcers. The Company’s common
stock is traded on The Nasdaq Stock Market under the symbol “POZN”. For
detailed company information, including copies of this and other press
releases, see POZEN’s website: www.pozen.com.
Source: POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030